2021Thank you for visiting us at the Forum EPFL22. October, 2021LYO-X will be recruiting at the Forum EPFL07. October, 2021
Come and see us in booth C15 at the SwissTech Convention Center in Lausanne....Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.22. June, 2021
2020Comprehensive mathematical model of the alternative complement pathway describing in vitro experimental- and clinical-data05. October, 2020
We recently published a comprehensive mathematical model of the alternative complement pathway in the PLOS Computational Biology journal. Building on previous modelling efforts, in this work...Population PK/PD Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation05. June, 2020
Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major...Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model17. April, 2020
Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance...
2022LYO-X and iBX are co-locating in the city centre of Basel!15. September, 2022
We are excited to announce that from the 1st July 2022, Integrated Biologix GmbH is co-locating with LYO-X AG in the beautiful city centre of Basel....LYO-X has moved to the center of the beautiful town of Basel09. May, 2022
We are excited to announce that on the 1st April 2022, LYO-X has moved to the center of the beautiful town of Basel!...